Study of FoxP3⁺ CD4⁺ CD25⁺ in systemic lupus erythematosus and rheumatoid arthritis
Farag Khalil a, Mohamed Nabil Rafat a, Abdelwahab Loftly a, Mahmoud H. Hemida a, Marwan Sayed a, Mamdouh Attia b

Departments of a Internal Medicine, b Clinical Pathology, Al Azhar University, Cairo, Egypt
Correspondence to Farag Khalil, BSc, MSc, MD, Alhusein University Hospital, Internal Medicine Department 7th Floor Cairo, 11311, Egypt. Tel: 01067775783; e-mail: dr.farag7070@azhar.edu.eg
Received 18 June 2018
Accepted 10 July 2018
The Egyptian Journal of Internal Medicine 2018, 30:289–299

Background
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) as autoimmune diseases arise owing to failure of immunological self-tolerance. One of the mechanisms employed to control these potentially damaging cells are regulatory T cells (Tregs). The importance of Tregs is underscored by the overwhelming inflammation and autoimmunity that result from their absence. Forkhead box p3 (FoxP3) is an important regulator of Treg function, and the expression of FoxP3 correlates with the expression of other Treg-associated markers such as CD25 and CTLA-4.

Aim
To investigate the frequency of FoxP3⁺ CD4⁺ CD25⁺high cells (Tregs) in peripheral blood from patients with SLE and those with RA.

Patients and methods
A total of 25 patients with SLE (15 patients with active SLE and 10 patients with inactive SLE), 25 patients with RA (15 patients with active RA and 10 patients with inactive RA), and 10 age-matched and sex-matched healthy controls were enrolled in the study. Patients underwent clinical and laboratory assessment. The frequency of Tregs was determined by flow cytometry.

Results
The distribution of FoxP3⁺ CD4⁺ CD25⁺high cells (Tregs) revealed a highly significant decrease in the frequency of Treg in patients with SLE compared with healthy controls. Moreover, patients with active SLE showed significantly lower Tregs percent when compared with inactive group. Moreover, the distribution of FoxP3⁺ CD4⁺ CD25⁺high cells (Tregs) revealed a high significantly decrease in the frequency of Treg in patients with RA compared with healthy controls.

Conclusion
CD4⁺ CD25⁺ FoxP3 Tregs (as a percent of total CD4 cells) were significantly lower in patients with SLE and those with RA when compared with healthy controls.

Keywords:
forkhead box p3, rheumatoid arthritis, systemic lupus erythematosus, regulatory T cells

Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production. The pathogenesis of SLE is not completely understood, with various types of immune cells being involved [1].

Rheumatoid arthritis (RA) is a common systemic autoimmune disease with chronic relapsing inflammation, primarily in peripheral joints. It is characterized by disturbed immune regulation, which induces a progressive cartilage and bone destruction [2,3].

Natural regulatory T cells (Tregs) are CD4⁺ CD25⁺ T cells generated in the thymus in early years of life with the ability to bind self-antigens by their T-cell receptor. They are distinguished from adaptive Treg that are induced in the peripheral blood by conversion of CD4⁺ CD25⁻ naive T cells in the presence of a particular microenvironment [4].

The importance of Treg in the development of autoimmune diseases was recognized by Sakaguchi and colleagues who were the first to show that transfer of CD4⁺ T cells depleted of CD25⁺ T cells, by specific monoclonal antibodies against CD25, into BALB/c athymic nude mice caused spontaneous development of T-cell-dependent autoimmune diseases (such as thyroiditis, gastritis, insulinis, sialadenitis, adrenitis, oophoritis, glomerulonephritis, and polyarthritis).
When these mice were reconstituted by CD4+ CD25+ T cells within a limited period after CD4+ CD25− T-cell transfer, the autoimmune disease development was successfully prevented [5].

The discovery of the forkhead winged-helix transcription factor forkhead box P3 (FoxP3) as master regulator for Treg added a key marker for this T-cell subset. FoxP3, in fact, is constitutively expressed at high levels in both natural and adaptive CD4+ CD25high Treg in human beings and mice. It is required for the natural Treg lineage commitment in the thymus and is essential in stabilizing and amplifying a Treg program, inclusive of anergy and defective interleukin 2 (IL-2) production, induced by interaction between Treg precursors and stromal cells in the thymus [6].

 Furthermore, it has been shown that persistence of expression of FoxP3 is important for maintaining suppressor function. Interestingly, it is now well accepted that FoxP3, despite being a distinctive marker for Treg, can also be expressed by human effector T cells after activation. However, its expression on these cells is transient and never reaches the expression levels displayed by Treg [7].

Although the concept of the preventive role of Treg in autoimmunity is widely accepted, data regarding SLE and RA are inconsistent. The studies on circulating Treg characterized phenotypically indicate either a decrease or increase or no change in their number compared with healthy controls. These discrepancies throughout the literature may be owing to the heterogeneity of the disease, studies in patients with different levels of disease activity, the possible effect of immunosuppressive treatment, and other factors [8,9].

The aim of the present study was to investigate the frequency of FoxP3+ CD4+ CD25high cells (Tregs) in peripheral blood from patients with SLE and RA.

**Patients and methods**

**Type of the study**
A cross-sectional observational study was conducted.

**Site and time of the study**
The study was conducted at the Internal Medicine Department, Faculty of Medicine, Al Azhar University, during the period from December 2016 to December 2017.

**Patients**
The study was conducted on 60 patients: 25 patients with SLE, where 22 patients were females and three were males; 25 patients with RA, where 20 patients were females and five were males; and 10 age-matched and sex-matched apparently healthy participants (male/female=2/8), who served as controls.

The patients were divided into three groups:

Group I: 25 patients with SLE, and they were divided according to SLE activity into two subgroups:
- Group IA: 15 patients with active SLE (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) >6).
- Group IB: 10 patients with inactive SLE (SLEDAI≤6).

Group II: 25 patients with RA, and they were divided according to RA activity into two subgroups:
- Group IIA: 15 patients with active RA (DAS-28≥3).
- Group IIB: 10 patients with inactive RA (DAS-28<3.2).

Group III: 10 age-matched and sex-matched apparently healthy participants (male/female=2/8).

**Ethical considerations**

(1) Before data collection, approval was granted by the ethical committee of Al Azhar Faculty of Medicine.

(2) Informed consent was obtained from every patient to participate in this study.

(3) Proper treatment for diseased cases was prescribed.

Patients with SLE were diagnosed according to SLE International Collaborating Clinics/American College of Rheumatology 2012 Criteria [10]. Patients with RA were diagnosed on the basis American College of Rheumatology /EULAR (2010) classification criteria for RA [11].

Any patient having coronary heart disease, diabetes, or end-stage renal disease, pregnant patients, patients on treatment by immunosuppressive drugs at the time of enrollment, and patient on treatment by high-dose glucocorticoids more than 20 mg/day at the time of enrollment were excluded from the study.

**Methods**
All participants were subjected to the following:

(1) Detailed history taking.

(2) Full clinical examination.

(3) Routine laboratory investigations, including erythrocyte sedimentation rate (ESR), C-reactive...
protein (CRP), fasting and 2-h postprandial blood glucose, complete blood count, complete urine analysis, and liver and kidney function tests.

(4) Measurement of proteins in 24 h urine (g/24 h).

(5) Antinuclear antibodies and anti-double stranded DNA antibodies (anti-dsDNA measurement was done by immunofluorescence technique, where titer of 1/40 or more is considered positive (done for patients with SLE only)).

(6) Serum complement level (C3 and C4) measurement was done by nephelometry (normal level of C3 is 84–160 mg/dl and for C4 12–36 mg/dl) (done for patients with SLE only).

(7) Rheumatoid factor measurement was done by turbidimetry. Normal level is 0–1 IU/ml (done for patients with RA only).

(8) Anti-cyclic citrullinated peptide measurement was done by chemiluminescence. Normal level is 0–5 U/ml (done for patients with RA only).

(9) The detection of percent of FoxP3+ CD4+ CD25high Treg was carried out by direct immunofluorescence technique using BD FACSC into flow cytometer using BD FACSdiva 8.02 system (Becton Dickinson Company, Town, USA), which was performed on the peripheral blood of both patients and controls.

(a) Two tubes each containing 50 μl of whole anticoagulated blood were set for each patient, one for the tested monoclonal antibodies and the other for isotype controls. Samples in each tube were lyed using 1-ml lysing solution and washed with PBS. Cell counts were adjusted at 5–10×10⁶/μl.

(b) The cells were stained with combinations of the following antibodies (5 μl) of anti-CD25-PE, anti-CD4-FITC cocktail (first tube) and PE isotype control (second tube).

(c) Tubes were then incubated in dark for 20 min followed by washing with PBS.

(d) The cell pellets were resuspended in 0.5 ml of freshly prepared fixation/permeabilization working solution and incubated for 30 min at 4°C in dark.

(e) This was followed by washing once with PBS and then washing once again with 1 ml of 1× permeabilization buffer.

(f) Ten microliters of PE-Cy5 FoxP3 or PE-Cy5 isotype control was added to respective tubes and incubated for 30 min at 4°C in dark.

(g) This was followed by washing once with PBS and then resuspension in PBS for analysis.

(h) Data acquisition and analysis were performed on BD FACSCanto flow cytometer using BD FACSdiva 8.02 system.

(i) Lymphocytes were gated via their forward and side scatter properties, and then CD4+ cells were identified based on their expression of CD4 versus side scatter properties.

(j) The gated CD4+ T cells were then assessed for both CD25 expressions, where CD4+ CD25high T cells were discriminated from CD4+ CD25dim T cells.

(k) Finally, CD4+ CD25high T cells were assessed for FoxP3 expression (Fig. 1). Treg were expressed as a percent of CD4+ T cells.

Statistical analysis

The data obtained from the history, clinical examination, and investigations were tabulated and statistically analyzed with the aid of computer’s GraphPad Prism program, version 7 [12]. Data were statistically described in terms of mean±SD, when appropriate. Spearman’s test was used for correlation analysis. Student’s t test was used for comparison of numerical variables between the study groups. P values less than 0.05 were considered statistically significant at the level of 95%.

Results

Frequencies of regulatory T cells

The distribution of FoxP3+ CD4+ CD25high cells (Tregs) revealed a highly significant decrease in the frequency of Treg in patients with SLE compared with healthy controls (1.08±0.29 and 2.46±0.7 for active SLE and control, respectively, P<0.0001) (1.54±0.23 and 2.46±0.7 for inactive SLE and control, respectively, P=0.0003) (Tables 1–4).

Moreover, patients with active SLE showed significantly lower Tregs percent when compared with inactive group (1.08±0.29 vs. 1.54±0.23, P=0.0004) (Table 5 and Fig. 2).

The distribution of FoxP3+ CD4+ CD25high cells (Tregs) revealed a highly significant decrease in the frequency of Treg in patients with RA compared with healthy controls (1.01±0.31 and 2.46±0.7 for active RA and control, respectively, P<0.0001) (1.52±0.24 and 2.46±0.7 for inactive RA and control, respectively, P=0.0003).

Moreover, patients with active RA showed significantly lower Tregs percent when compared with the inactive group (1.01±0.31 vs. 1.52±0.24, P=0.0002) (Table 5 and Fig. 2).
Correlations between Treg (percent) and parameters of lupus activity

In the present study, positive correlations were observed between Treg (percent) and C3 ($r=0.5714$ and $P=0.0028$) and C4 ($r=0.2870$ and $P=0.0185$) in patients with SLE, whereas negative correlations were observed between Treg (percent) and ESR ($r=-0.4933$ and $P=0.0122$), 24-h urinary protein ($r=-0.4981$ and

Table 1 Comparison between clinical variables in patients with systemic lupus erythematosus and control groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group IA (active SLE)</th>
<th>Group IB (inactive SLE)</th>
<th>Group III (control)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group IA and group III</td>
<td>Group IB and group III</td>
<td>Group IA and group IB</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>33±8.6</td>
<td>32.6±5.15</td>
<td>32±6.61</td>
<td>0.6023</td>
</tr>
<tr>
<td>Age of onset (years)</td>
<td>28.27±7.6</td>
<td>25.3±8.68</td>
<td></td>
<td>0.3758</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>6.4±3.69</td>
<td>6.3±4.21</td>
<td></td>
<td>0.5784</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>68.13±9.64</td>
<td>68.5±9.51</td>
<td>69.9±4.95</td>
<td>0.5999</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>171±8.18</td>
<td>169.1±6.5</td>
<td>172.3±5.7</td>
<td>0.6681</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.5±3.2</td>
<td>24±3.42</td>
<td>23.5±1.99</td>
<td>0.9448</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>149.7±23.03</td>
<td>125.5±16.06</td>
<td>120.5±6.85</td>
<td>0.0085**</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>94.67±15.06</td>
<td>78.5±13.13</td>
<td>76.5±7.09</td>
<td>0.0111*</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>16.3±5.4</td>
<td>1.6±0.48</td>
<td></td>
<td>&lt;0.0001****</td>
</tr>
</tbody>
</table>

SLEDAI, systemic lupus erythematosus disease activity index. Data are presented as mean±SD. SLE, systemic lupus erythematosus. *, **, ***, **** Denote the degree of significance low to high and very high significance.

Correlations between Treg (percent) and parameters of lupus activity

In the present study, positive correlations were observed between Treg (percent) and C3 ($r=0.5714$ and $P=0.0028$) and C4 ($r=0.2870$ and $P=0.0185$) in patients with SLE, whereas negative correlations were observed between Treg (percent) and ESR ($r=-0.4933$ and $P=0.0122$), 24-h urinary protein ($r=-0.4981$ and

Show the stages of lymphocytes a: T- Lymphocyte, b: CD4+, c: CD25+, d: Foxp3.
Correlations between Treg (percent) and parameters of rheumatoid arthritis activity

In the current study, negative correlations were observed between Treg (percent) and ESR ($r = -0.6018$ and $P = 0.0015$), CRP ($r = -0.5931$ and $P = 0.0018$), and DAS-28 score ($r = -0.6825$ and $P = 0.0002$) in patients with RA.

Discussion

The human immune system is equipped with different mechanisms involved in maintaining immune tolerance and protection against autoimmunity. Treg lymphocytes are the key cells controlling the autoimmunization process. Their role is illustrated by an active and dominant control over the function of effector T cells [13].

SLE is a chronic autoimmune disease that can be fatal. As occurs in other autoimmune diseases, the immune system attacks the body’s cells and tissues, resulting in inflammation and tissue damage [14]. It is associated with abnormal immune response including production of autoantibodies; abnormalities of the complement system, T cell–B cell interaction, phagocytosis, and T-cell hyperactivity represent a central feature of SLE [15].
There is a connection between lupus and the disturbance of Tregs that plays an important role in maintaining a healthy immune system. Several studies have demonstrated that decreased numbers and/or function of Tregs contribute to the pathogenesis of SLE [16].

RA is a chronic inflammatory autoimmune disease arising from a breakdown in self-tolerance, which leads to aberrant immune responses to autoantigens. Tregs constitute one of the key mechanisms of self-tolerance and are a major focus of study in RA to design new and improved therapies to reinstate self-tolerance [17].

In this study, we investigated the percent of CD4+ CD25+ FoxP3+ Tregs in patients with SLE and patients with RA, as well as the correlation with other parameters of disease activity.

The present study included 50 patients divided into group IA (15 patients with active SLE), group IB (10 patients with inactive SLE), group IIA (15 patients with active RA), and group IIB (10 patients with inactive RA). CD4+ CD25+ FoxP3+ Tregs were estimated for all patients, and their results were compared with those of 10 controls (group III).

In the present cross-sectional, observational study on patients with SLE and patients with RA, results revealed that the level of CD4+ CD25+ FoxP3+ Tregs (as a percent of total CD4 cells) was significantly lower in patients with SLE and patients with RA when compared with healthy controls. Moreover, patients with active SLE and RA showed significant difference when compared with inactive groups.

In the present study, there was a significant correlation between Treg percent and C3, C4 levels, ESR, and SLEDAI in patients with SLE, and a significant correlation between Treg percent and ESR, CRP, and DAS-28 in patients with RA.

Our results of decreased Treg in patients with SLE when compared with healthy controls are in agreement with many other studies [18–23], which investigated

Table 4 Comparison between laboratory variables in patients with rheumatoid arthritis and control groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group IIA (active RA)</th>
<th>Group IIB (inactive RA)</th>
<th>Group III (control)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>11.27±1.42</td>
<td>12.8±0.87</td>
<td>13.43±0.72</td>
<td>0.0002***</td>
</tr>
<tr>
<td>WBC (x1000/ml)</td>
<td>5.93±1.68</td>
<td>6.42±2.32</td>
<td>6.9±1.5</td>
<td>0.1517</td>
</tr>
<tr>
<td>Platelets (x1000/ml)</td>
<td>234.5±85.3</td>
<td>229.4±66.6</td>
<td>289±88.6</td>
<td>0.1057</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>84.27±22.8</td>
<td>26±9.9</td>
<td>8±1.6</td>
<td>&lt;0.0001****</td>
</tr>
<tr>
<td>CRP</td>
<td>21.9±6.85</td>
<td>8±1.49</td>
<td>0.8±0.4</td>
<td>&lt;0.0001****</td>
</tr>
<tr>
<td>ALT (IU/ml)</td>
<td>27.1±13.8</td>
<td>23.5±8.39</td>
<td>18.7±7.68</td>
<td>0.0935</td>
</tr>
<tr>
<td>AST (IU/ml)</td>
<td>25.1±11.4</td>
<td>22.5±7.6</td>
<td>20.7±7</td>
<td>0.2275</td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>1.12±0.3</td>
<td>0.9±0.21</td>
<td>0.85±0.13</td>
<td>0.0160*</td>
</tr>
<tr>
<td>BUN</td>
<td>21.9±10.1</td>
<td>20.3±7.3</td>
<td>14.5±1.73</td>
<td>0.0315*</td>
</tr>
<tr>
<td>Rheumatoid factor positivity</td>
<td>11/15 (73.3)</td>
<td>7/10 (70)</td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>ACCP positivity</td>
<td>12/15 (80)</td>
<td>7/10 (70)</td>
<td></td>
<td>NS</td>
</tr>
</tbody>
</table>

| Data are presented as mean±SD and n/N (%). ACCP, anti-cyclic citrullinated peptide; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; WBC, white blood cell. *, **, ***, **** Denote the degree of significance low to high and very high significance.

Table 5 Treg percentage in the studied groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group IA (active SLE) (N=15)</th>
<th>Group IB (inactive SLE) (N=10)</th>
<th>Group IIA (active RA) (N=15)</th>
<th>Group IIB (inactive RA) (N=10)</th>
<th>Group III (control) (N=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treg (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>1.08±0.29</td>
<td>1.54±0.23</td>
<td>1.01±0.31</td>
<td>1.52±0.24</td>
<td>2.46±0.6</td>
</tr>
<tr>
<td>Range</td>
<td>0.66–1.62</td>
<td>1.16–1.92</td>
<td>0.63–1.72</td>
<td>1.17–1.88</td>
<td>1.8–3.66</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group IA and group III</td>
<td>&lt;0.0001****</td>
<td>0.0003****</td>
<td>0.0001****</td>
<td>0.0004****</td>
<td>0.0002****</td>
</tr>
<tr>
<td>Group IB and group III</td>
<td></td>
<td></td>
<td>0.0003****</td>
<td>0.0004****</td>
<td></td>
</tr>
<tr>
<td>Group IA and group III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RA, rheumatoid arthritis; SLE, systemic lupus erythematosus. **** Denote the degree of significance low to high and very high significance.
the frequencies of circulating Treg in SLE and found a significant decrease in circulating Treg in peripheral blood of diseased patients when compared with controls.

In accordance to these results, Szmyrka-Kaczmarek et al. [24] found that the proportion of peripheral blood Treg cells in SLE group was significantly lower than that in healthy control group. The finding of reduced level of Tregs in SLE was explained by many studies on the role of Treg in autoimmune diseases especially in SLE, which showed that the pathogenesis of SLE involves breakdown of immunologic self-tolerance resulting in the development of autoantibodies. Many T-cell and B-cell abnormalities have been described, and these include defects in Tregs that normally prevent pathologic self-reactivity [25,26].

Iikuni and colleagues adds supportive evidence to this explanation, as they stated that in humans with SLE, the Treg can directly suppress autoantibody-producing B cells, including those that belong to pathogenic subtypes that are found expanded in active SLE. The cell-to-cell dependent mechanisms of suppression of autoreactive B cells by Treg in SLE, that could represent an attempt to directly control humoral autoimmunity, involve the release of perforin and granzyme by activated Treg and the induction of apoptosis in these autoreactive B cells [27].

In an attempt to understand the role of Treg in pathogenesis of SLE, Scalapino and Daikh [28] stated that, in addition to the B cells, Treg also

---

**Figure 2**

Show that significant deletion of T-Reg percentage in patients with SLE & RA in comparison to control group.

**Figure 3**

Show Positive correlations is observed between T-Reg (Percent) and C3 \( r = 0.5714 \) & \( P = 0.0028 \) (Both are depleted).

**Figure 4**

Show Positive correlations were observed between T-Reg (Percent) and C4 \( r = 0.4672 \) & \( P = 0.0185 \).

**Figure 5**

Show Negative correlations is observed between T-Reg (Percent) and ESR \( r = 0.4399 \) & \( P = 0.0122 \).
suppress lupus CD4+ T cells that provide help to autoantibody-producing B cells. This intermediate suppression of humoral immune responses by Treg in SLE involves the induction of a state of hyporesponsiveness to stimulation (anergy) in the CD4+ T helper cell (Th cell) and might represent a modality for the host to more effectively reduce the production of pathogenic autoantibodies, as both hyperactive Th cells and B cells would be rendered inactive by suppressor Treg.

Recently, it was suggested that autoimmunity in SLE may result when CD4+ T cell differentiation is biased away from Treg toward the Th17 cell phenotype. Szymyka-Kaczmarek et al. [24] assessed Th17/Treg ratio in patients with SLE and found that the ratio of Th17 cells to Treg was markedly higher in patients with SLE than in the control group.

Talaat and colleagues investigated the cytokines related to Tregs [transforming growth factor beta 1 (TGF-β1)] and that related to Th17 (IL-17), and they found that patients with SLE have significantly higher levels of IL-17 but slight reduction of TGF-β levels compared with controls. Moreover, this could imply skewing of T cells toward Th17 cells and breaking Th17/Treg balance [29].

Contrary to these finding, some studies report increased levels of Treg cells in SLE compared with those in healthy controls [30], or a resistance of lupus effector T cells to Treg cell suppression instead of defects of SLE Treg cells [31].

It is evident from the analysis of the different studies that the data arising from the evaluation of the global CD4+ CD25+ cell population are inconclusive,
probably because of the extreme heterogeneity of this T-cell subset. Indeed, as the percentage of circulating Treg in humans should be less than 2–3%, the very high numbers and the wide variability of the reported percentages of the cell subpopulations considered in these studies, ranging from 6.5 to 31.3% in normal controls and from 6 to 37.8% in patients with SLE, appear to support this hypothesis [4].

Most of the earlier studies focused only on phenotypic characterization of circulating T cells, but they were limited by difficulties in distinguishing Treg cells from simply activated T cells bearing the CD25 surface molecule, as Treg cells in humans are more represented in CD25\(^{\text{high}}\) cell fraction, which, however, is difficult to be unequivocally defined. It has been demonstrated, in fact, that the higher is CD25 surface expression the higher is suppressor activity. To more accurately discriminate between Treg and activated T cells, additional evaluations of FoxP3 mRNA expression within the CD4\(^{+}\) CD25\(^{+}\) cell population have been performed in some studies in patients with SLE. Recently, a more extensive analysis of FoxP3 expression has been possible with the availability of new tools for FoxP3 detection by flow cytometry that have improved data reliability [4].

Analysis of the results about FoxP3 cell expression in SLE is more complex, as the evaluation of its expression has been carried out with different methods and it has been analyzed within different cell subsets. However, it is of interest the observation that FoxP3 expression, when evaluated in both CD25\(^{+}\) and CD25\(^{+}\) cell subsets, seems to be reduced in the cell population bearing the CD25 and increased in the T-cell subset lacking this surface molecule [32]. Interestingly, similar results have been reported in a cohort of patients with new-onset SLE [21,33].

Pathogenic basis of SLE may result also by an imbalance between effector and Tregs and not only by Treg cell impairment only. There is some evidence that impaired suppressor function is demonstrable when Treg are co-cultured with autologous effector T cells but not with effector T cells obtained from healthy donors, thereby suggesting a possible resistance of effector T cells to Treg inhibition [34,35]. Moreover, these data, however, have not been confirmed in subsequent studies [36].

It is conceivable that many discrepancies about Treg findings in SLE may be dependent on both different phases of disease activity and immunosuppressive treatments that may affect viability and function of T cells. These findings are in agreement with the general observation that numerically decreased and/or functionally defective Treg seem to be usually associated with active phases of the disease, whereas a phenotypic and functional picture similar to controls is the most frequent finding in inactive SLE [20,33,37].

In the present study, there was a significant correlation between Treg percent and C3, C4 levels, ESR, and SLEDAI in patients with SLE. These results were discordant with Lee et al. [35], who found a nonsignificant correlation with either of C3 and C4 levels. However, they found a significant correlation with ESR levels.

Moreover, a significant negative correlation was found between Treg and anti-dsDNA antibody in patients with SLE, which is in agreement with Ma et al. [23], who found that the numbers of CD4\(^{+}\) CD25\(^{+}\) FoxP3\(^{+}\) in the anti-dsDNA\(^{+}\) patients were significantly fewer than those in the anti-dsDNA\(^{-}\) patients.

Our result showed a significant negative correlation between Treg and SLEDAI in patients with SLE, which is in agreement with Ma et al. [23].

Our results of decreased Treg cells percent in active SLE group compared with inactive group suggest an important role of these cells in pathogenesis of lupus activity. Moreover, a significant correlation of Treg with marker of disease activity is another evidence that can support this suggestion.

Our result of decrease Treg cells percent in RA compared with control group was in agreement with other groups [38–43].

The exact mechanisms that reduce the level of Tregs in RA are not clear. It was suggested that regulatory cells are recruited to sites of inflammation in an attempt to suppress disease, resulting in a relative reduction in the peripheral blood population [38].

Reports of a higher number of Tregs present in synovial fluid than that in the peripheral blood in patients with RA support this explanation. Tregs accumulated in inflamed joints express high levels of surface and intracellular CTLA-4, GITR, OX-40, and FoxP3 [44].

Moreover, Tregs were found to display increased tendency to undergo spontaneous apoptosis in active RA. Some studies [45–47] proposed that in an
inflammatory condition like RA, it is quite possible that Tregs in the presence of the different proinflammatory cytokines will become unstable and convert to pathogenic T cells. This decline in Treg numbers may predispose to persistent autoimmune diseases including RA [38].

Recently, it was suggested that decreased level of Tregs in RA may be owing to transdifferentiation to Th17 cells [48].

Al-Zifzaf and colleagues who investigated the frequency of FoxP3+ CD4+ CD25+high cells in 40 Egyptian patients with RA also studied TGF-β: IL-17 ratio to throw light on the imbalance between these two cytokines in RA. They found that the frequency of Tregs was significantly decreased among patients with RA compared with control (2.37±0.73 and 6.88 ±7.26%, respectively, P=0.000), and TGF-β: IL-17 ratio was lower in patients with RA compared with controls [49]. Similar results were found by Gaafar and colleagues who assessed the Treg/Th17 ratio and Th17-related cytokines, in peripheral blood of Egyptian patients with RA. They found that patients with active RA revealed an obvious increase in peripheral Th17 frequencies and levels of Th17-related cytokines and a significant decrease in Treg (CD4+ CD25+ FoxP3+) frequencies when compared with healthy controls [50].

Contrary to our results, there are reports of increased Tregs in peripheral blood of patients with RA [51,52], but in these research studies, the authors assessed different CD4+ CD25+ T cell subtypes (including CD4+ T-cells expressing low levels of CD25 and those expressing FoxP3 and those not expressing it), which could account for the discrepancy in the results.

We found a significant negative correlation between DAS-28 score and the decrease in frequency of Treg. The lower the frequency of Tregs, the higher the DAS-28 score reflecting higher disease activity, and also ESR and CRP. This may indicate the importance of Treg cells in pathogenesis of RA activity, but the precise role of their deficiency in pathogenesis of activity needs to be defined by further studies. Others did not report any correlation between Treg frequencies or cytokines with DAS-28 score [43,49].

Moreover, patients with active SLE and those with RA showed significantly lower Treg cells percent than inactive groups, and CD4+ CD25+ FoxP3 Tregs percentage of CD4 cells was significantly correlated with ESR, C3, C4 levels, and SLEDAI score in patients with SLE. Moreover, it was significantly correlated with ESR, CRP, and DAS-28 score in patients with RA, which is the main marker of disease activity, indicating a power to detect patients with active disease.

Acknowledgements
The authors thank members of the laboratory in Al Hussein University Hospital for the aid in preparation of this manuscript.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
12. Prism 2015 7 for Windows runs under either the 32- or 64-bit versions of Windows Vista, 7, 8 or 10. Prism will run in a screen as small as 800 × 540. While it runs fine on 64 bit versions of Windows, it is a 32 bit program.


Zare H-R, Habbagahi M, Vahdati A, Habbagahi Z. Patients with active rheumatoid arthritis have lower frequency of nTregs in peripheral blood. Iran J Immunol 2015; 12:166–175.


